Aligning Medical Schemes with National Health Insurance South Africa

By João L. Carapinha

October 30, 2025

The National Health Insurance initiative in South Africa is advancing toward universal health coverage, and the recent CMS Annual Report 2024/25 highlighted the regulator’s pivotal role in supporting this framework by integrating public and private healthcare sectors. The report highlights key strategies such as reforms to Prescribed Minimum Benefits (PMB), the development of standardized base benefit packages, and enhancements to risk pooling mechanisms, all designed to position medical schemes as complementary funders in an NHI ecosystem. The report presents quantitative data illustrating the private industry’s scale, including 9.13 million beneficiaries across 71 schemes and a solvency ratio of 43.45%, while emphasizing challenges like rising claims ratios exceeding 100% in some schemes and the need for agile regulation to ensure affordability and equity.

PMB Reviews Tackle Chronic Care Gaps

Central to the report’s analysis is the ongoing review of PMBs, which are mandatory minimum benefits ensuring non-discriminatory coverage for essential chronic conditions, such as HIV affecting 800,000 beneficiaries and hypertension programs serving 3.6 million individuals. The Council for Medical Schemes (CMS) collaborates with the National Department of Health through the PMB Review Advisory Committee to refine primary healthcare (PHC) packages, incorporating preventative principles as recommended by the Health Market Inquiry (HMI). This effort has produced 10 PMB definition guidelines to standardize interpretations and reduce disputes, such as persistent short payments, supported by real-time data from members and providers. These reforms culminate in a clinically appropriate base benefits package that aligns with population health needs, simplifying beneficiary options across diverse schemes and addressing under-pricing deficits of R6.73 billion in 2023, thereby enhancing the sector’s readiness for equitable, sustainable coverage.

Risk Pools Evolve Against Fraud Threats

The report details CMS’s strategic adaptations to NHI challenges, including redefining its oversight to focus on complementary roles for medical schemes, which cover approximately 15.7% of the population through private risk pools. Key initiatives involve updating demarcation regulations to distinguish schemes from indemnity products, as outlined in the Low-Cost Benefit Options (LCBO) Guideline Report submitted to the Minister in November 2023, with exemptions for insurers extended to March 2027 to preserve risk-pooling integrity. Fraud, Waste, and Abuse (FWA) mitigation is bolstered through renewed charters and the Section 59 Investigation’s findings on discriminatory practices against black providers, introducing standardized detection frameworks and Tribunal processes. These measures, informed by 11 Memoranda of Understanding (MoUs) for stakeholder collaboration and research outputs like five policy bulletins, aim to curb costs in a system facing 8.70% monthly expenditure increases to R2,000.57 per beneficiary, fostering efficiencies such as 99.19% managed care coverage that can transfer to NHI contracting models.

Solvency Holds Firm Amid Economic Strain

Economic constraints, including a projected 1% GDP growth for 2024 and high unemployment, exacerbate affordability issues, with total contributions reaching R226.94 billion (excluding savings accounts) amid a 6.40% inflation-driven rise and persistent out-of-pocket (OOP) payments of R43.3 billion. The report quantifies industry solvency at 43.45%, down from 47.14% in 2022 but above the 25% minimum, while claims ratios average 95.88% due to pent-up COVID-19 demand and utilization trends. Efficiency Discount Options (EDOs), now covering 37% of beneficiaries (up from 20% in 2017), demonstrate private sector mechanisms for cost containment, monitored through Scheme Risk Measurement (SRM) tools. These dynamics highlight CMS’s 96.43% performance score in agile responses, despite levy-dependent budget limitations of R259 million, positioning the sector to support National Health Insurance South Africa’s goal of minimizing financial barriers while maintaining financial sustainability.

HEOR Boosts Value-Based NHI Shifts

The report’s findings carry significant implications for Health Economics and Outcomes Research (HEOR) by promoting value-based healthcare (VBHC) shifts from fee-for-service models, potentially lowering costs through standardized benefits and FWA controls in an NHI context. For market access and reimbursement, the base benefits package and LCBO guidelines could streamline pricing negotiations via forums like the Multilateral Negotiation Forum (MLNF), reducing disputes and enhancing equity, particularly for underserved communities as per HMI recommendations. Broader industry trends, such as digital transformation for real-time data oversight, align with global HEOR emphases on evidence-based reforms which note that integrated risk pools could cut OOP expenditures in transitional systems. Ultimately, these strategies position medical schemes to bolster NHI’s UHC objectives, improving health outcomes through sustainable funding while mitigating solvency risks in a resource-constrained environment.

Reference url

Recent Posts

Medical Device Innovation South Africa: Breaking Down Systemic Barriers

By HEOR Staff Writer

April 27, 2026

Medical device innovation South Africa is hindered by deep structural obstacles that prevent locally developed technologies from reaching patients, despite the country’s considerable technical expertise. South Africa’s medical technology sector remains trapped in a cycle of heavy import dependenc...
Expanding Access to Hormonal IUDs in South Africa through Generic Innovation
The launch of AVIBELA marks a significant milestone for hormonal IUD South Africa, introducing the country’s first generic levonorgestrel 52 mg intrauterine device. Developed by Medicines360 and commercialized in partnership with Pharma Dynamics, AVIBELA is more than 99% effective at preventing p...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies

By João L. Carapinha

April 23, 2026

Europe Pharmaceutical Access is at a “very critical point,” according to Emer Cooke, Executive Director of the European Medicines Agency (EMA). The number of new drug launches in Europe has fallen by more than a third since U.S. President Donald Trump’s “most-favored-nation” (MFN) drug pricing po...